Physician
Rheumatology
Dr. Craig W. Wiesenhutter, MD
Craig W. Wiesenhutter, MD is an expert in the field of Rheumatology. He attended Albert Einstein College of Medicine of Yeshiva University. He received 3 awards: "CMS Meaningful Use Stage 1 Certification", "Fellow" and "Fellow (FACR)". Craig Wiesenhutter is also published. He has 14 publications published. The lastest publication: "Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial.' Craig W. Wiesenhutter, MD accepts Medicare.
Publications
- Cevimeline for the treatment of xerostomia in patients with Sjögren Syndrome: a randomized trial.
- Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene:...
- The low-throughput protein A adsorber: an immune modulatory device. Hypothesis for the mechanism of action in the treatment of rheumatoid Arthritis.
- Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoArthritis: A randomized, double-blind, placebo-controlled trial.
- Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid Arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators...
- IgG aggregates of different sizes stimulate or suppress Ig secretion by human lymphocytes in vitro.
- A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid Arthritis.
- Panhypogammaglobulinemia in Systemic lupus erythematosus: in vitro demonstration of multiple cellular defects.
- CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid Arthritis.
- Treatment of patients with refractory rheumatoid Arthritis with extracorporeal protein A immunoadsorption columns: a pilot trial.
- In vitro T lymphocyte proliferative response to Yersinia enterocolitica in Reiter's Syndrome. Lack of response in other HLA-B27 positive individuals.
- A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumato...
- Efficacy of tacrolimus in rheumatoid Arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Schools
Albert Einstein College of Medicine of Yeshiva University
Procedures Preformed
- Joint Drainage
- Myofascial Trigger Point Injection
- Steroid Injection
Conditions Treated
- Antiphospholipid Syndrome (APS)
- Arthritis
- Bursitis
- Calcium Pyrophosphate Dihydrate Deposition Disease (CPPD)
- View All
Doctors Specialties
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow
- Fellow (FACR)
Education
-
UCLA Medical Center
-
University of Southern California - LAC+USC Medical Center
-
Albert Einstein College of Medicine of Yeshiva University
Drug Facts
| NPI NUMBER |
|
1205980422 |
| NPPES Provider LastName |
|
WIESENHUTTER |
| NPPES Provider FirstName |
|
CRAIG |
| NPPES Provider ZIPCode |
|
838142644 |
| NPPES Provider State |
|
ID |
| Specialty Description |
|
Rheumatology |
| Total Claim Count |
|
3615.0 |
| Distinct Opioid Count |
|
4.0 |
| Opioid Claim Count |
|
390.0 |
| Percent Opioid Claims |
|
10.79 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1205980422 |
| Last Name Of The Provider |
WIESENHUTTER |
| First Name Of The Provider |
CRAIG |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.